AIR PRODUCTS AND CHEMICALS, INC. (APD): what the price requires
At today's price, AIR PRODUCTS AND CHEMICALS, INC. (APD) is priced for today's economics sustained for ~5.5 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.
Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/APD
Headline
| Field | Value |
|---|---|
| Ticker | APD |
| Company | AIR PRODUCTS AND CHEMICALS, INC. |
| Current price | $302.86/sh |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | whole-company |
| Operating margin needed | 17.9% |
| Operating margin (mid-cycle) | 14.7% |
| Margin expansion implied | +3.2pp |
| Trailing margin (depressed year) | -0.4% |
| Must persist for | 5.5y |
| Multiple paid | 47x mid-cycle operating income |
The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.
Solve inputs: computed at a 7.4% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.2 years.
Reconcile: at the x-ray's 9.3% required return this reads ~9.4 years; the models below use their own rates.
How unusual the bet is: elevated
| Reference | Value |
|---|---|
| vs own history | +0.81σ |
| sustained it ~5.5 years at this level | 31% |
| implied end-window share | 0% |
Valuation X-Ray
Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 2.48x | 5 | expensive |
| Earnings | 2.40x | 3 | expensive |
| Relative | 2.40x | 5 | expensive |
| Growth | 1.29x | 2 | expensive |
Families that call it expensive: Asset, Earnings, Relative
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.
Per-Model Detail (n=15)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $242.03 | 1.25x | yes | Reference only (OCF-based, capex excluded): OCF $2.9B |
| DCF Exit Multiple | Growth | $0.00 | — | no | Negative/zero FCF or EBITDA — equity value floored at $0 |
| Relative Valuation | Relative | $174.15 | 1.74x | yes | P/E 19.41x (blended: static sector reference 14x + trailing (TTM) 32x), scenarios: 16.1x / 19.4x / 22.7x (bear / base = reference held flat / bull), EV/EBITDA 13.19x |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $102.21 | 2.96x | yes | BV/sh $70.21, ROE (TTM) 13.5%, ke 9.3% |
| Two-Stage Excess Return | Asset | $122.17 | 2.48x | yes | 5yr excess ROE then converge to ke=9.3% |
| Discounted Future Market Cap | Growth | $229.27 | 1.32x | yes | Rev $12.5B, growth 4% (input: historical growth; tapered), Terminal P/S: 4.5x / 5.4x / 6.3x (bear / base = today's held flat / bull, cap 8x) |
| Peter Lynch Fair Value | Relative | $126.25 | 2.40x | yes | EPS $9.46, growth 13% (input: historical EPS growth), PEG=2.40 (Overvalued) |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | $126.21 | 2.40x | yes | Normalized EBIT (5y avg op income, one-time charges added back) $3.05B × (1−18%) / WACC 9.2% → EPV (no growth) |
| Residual Income | Asset | $126.48 | 2.39x | yes | BV $70.21 + 5yr PV of (ROE (TTM) 13.5% − Kₑ 9.3%) × BV; BV grows 8.8%/yr |
| Graham Number | Asset | $122.25 | 2.48x | yes | √(22.5 × EPS $9.46 × BVPS $70.21) — Graham's conservative floor |
| EV/EBITDA Relative | Relative | $95.82 | 3.16x | yes | EBITDA $2.67B × sector EV/EBITDA 8.0x |
| FCF Yield | Earnings | — | — | no | — |
| SBC-Adj FCF Yield | Earnings | — | — | no | — |
| Ben Graham Formula | Earnings | $279.01 | 1.09x | yes | EPS $9.46 × (8.5 + 2×13.3%) × (4.4 / 5.3%) |
| ROIC-Justified P/B | Asset | $30.23 | 10.02x | yes | BV $70.21 × (ROIC 4.0% / WACC 9.2%) |
| P/Sales Sector | Relative | $83.88 | 3.61x | yes | Revenue $12.46B × sector P/S 1.5x |
| PEG Fair Value | Relative | $189.37 | 1.60x | yes | EPS $9.46 × (PEG 1.5 × growth 13.3% (input: historical EPS growth)) → PE 20.0x |
| Earnings Yield | Earnings | $102.27 | 2.96x | yes | EPS $9.46 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net debt | $17.1b |
| Net debt / NOPAT (after-tax) | 11.57x |
| Net debt / operating income (pre-tax) | 9.49x |
| Interest coverage | 8.7x |
| Share count CAGR (dilution) | 0.0% |
| Burning cash | no |
Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 14.7%); the trailing year was depressed.
Bullet Takeaways
- Air Products sells industrial gases under long-term on-site and merchant contracts, a business where customers sign up for years of supply, which is why earnings grew through the cycle and the dividend has risen for 44 consecutive years.
- The defining risk is the price itself: at roughly 45 times through-cycle operating income, the market is paying a multiple no standard valuation method reaches, so the premium rests entirely on the giant clean-hydrogen projects converting to contracted cash flow.
- Watch capital discipline under new leadership; fiscal 2026 capex was cut by more than $1 billion to about $4 billion, the clearest signal yet that management is reining in the megaproject spend that built the balance sheet's $17 billion of net debt.
Bull Case
The earnings trajectory is the cleanest part of the Air Products story, and it points up. Fiscal first-quarter 2026 GAAP operating income reached $735 million, up 14% year over year, with EPS of $3.16 ahead of the $3.04 consensus and revenue of $3.1 billion. Management affirmed full-year guidance implying 7% to 9% earnings improvement at the midpoint. This is a base business compounding steadily, and the dividend record underlines it: the quarterly payout rose to $1.81, the 44th consecutive annual increase. Few industrial companies can claim that kind of through-cycle consistency.
The reason sits in the contract structure, which is the real moat. The 10-K describes serving customers "through either our on-site or merchant supply mode depending on various factors, including the customer's volume requirements and location," with on-site gases serving customers "primarily in the energy production" and heavy-process industries. On-site plants are built next to a customer and sold under long-term, often take-or-pay contracts, which means the revenue is contracted years in advance and largely insulated from the spot economy. That is what lets Air Products earn an 18.4% trailing operating margin and plan multi-year capital programs against demand it has already signed. Industrial gases is a structurally consolidated industry; against a chemicals cohort that includes Linde, DuPont, and Albemarle, the gas majors are the franchises with the most contracted, least cyclical revenue.
The bull's optionality is the clean-hydrogen build-out, now being managed with more discipline. The company won NASA supply contracts worth more than $140 million for liquid hydrogen and is negotiating a distribution agreement to move renewable ammonia into European green-hydrogen production. More important than any single award, fiscal 2026 capex was cut by over $1 billion to about $4 billion, a shift from open-ended megaproject spending toward funding the projects that have contracted offtake. If the new management team converts the existing project pipeline into contracted cash flow while spending less to do it, the earnings base steps up without the balance sheet stretching further. That is the bet the premium is paying for.
Bear Case
The bear case is about capital allocation, because that is where the risk in Air Products actually lives. The company carries about $17 billion of net debt, roughly 9.3 times trailing operating income, a leverage level built up funding clean-hydrogen megaprojects whose returns are still in the future. The 10-K's own disclosures show how speculative parts of that program have been: it holds a variable interest in World Energy through a financing receivable "that was fully reserved", a write-down on exactly the kind of energy-transition bet that drove the spending. The new capex cut of more than $1 billion is welcome, but it is also an admission that the prior pace was too aggressive, and the debt taken on to fund it does not shrink because the spending slowed.
That feeds the central problem, which is what the price assumes. No family of valuation method reaches the current price: it is rich on assets, on earnings power, on peer multiples, and even on forward growth, all reading the price roughly 2.2 to 2.3 times above where they land. Inverted, the price embeds about 24.5% annual operating-income growth for five years on the company's own through-cycle margins, a multiple near 45 times normalized operating income. Air Products has grown, but compounding mid-cycle operating profit at 24.5% for five straight years is a pace only about a third of comparable fast-growers have sustained. The entire premium rests on the hydrogen projects delivering that growth, and the contracted base business, growing 7% to 9%, does not get there on its own.
The structural risk is timing and conversion. Industrial gas megaprojects take years to build and commission, and the green-hydrogen projects depend on policy support, offtake demand, and execution that has already produced one reserved receivable. Interest coverage near 8 times is adequate but not generous for a company this levered, and the share count has been flat, so there is no buyback cushioning the per-share math. The bear does not argue the base business is bad; it argues the price has front-loaded a decade of successful project conversion into today's multiple, and any slip in the hydrogen timeline leaves a premium with nothing standard underneath it.
Valuation
The price is making a large bet, and it is worth stating plainly. Inverted, today's price embeds roughly 24.5% annual operating-income growth for five years, valued on the company's through-cycle margins rather than a trough quarter, which works out to about 45 times normalized operating income. The base business is guided to grow 7% to 9% this year. The gap between those two numbers is the clean-hydrogen optionality the market is capitalizing in advance, and the valuation question is whether the megaproject pipeline closes that gap or whether the premium is paying for growth that arrives slower and costs more than the price assumes.
The methods are unanimous and unusually emphatic: none of them reaches the price. The asset-value and earnings-power lenses sit at roughly 0.4 times the price, the peer-multiple lens similar, and even the forward-growth methods, which credit future expansion, land below it at about 0.7 times. When every family says a stock is expensive, including the growth methods, the price is a bet beyond what any standard frame supports, and the report should say so directly. There is no conservative method here defending the level. The premium is entirely a wager on the hydrogen build-out converting to contracted earnings, and the spread between the price and the methods is the size of that wager.
Solvency is where the wager meets the balance sheet, and it bears watching. Net debt of about $17 billion is 9.3 times trailing operating income and over 11 times after-tax operating profit, with interest coverage near 8 times. That is investment-grade but meaningfully levered for an industrial, and it was built funding projects that are not yet generating their full returns. The fiscal 2026 capex cut of more than $1 billion is the company beginning to deleverage the spending side, and the 44-year dividend record signals management intends to protect the payout. Against the chemicals cohort, Air Products carries both the most contracted base business and the largest unproven capital program, and the price is paying full freight for the second while the first does the steady work.
Catalysts
The fiscal first-quarter 2026 print was a clear beat and the stock responded. Air Products reported EPS of $3.16 against a $3.04 consensus, GAAP operating income of $735 million up 14% year over year, and revenue of $3.1 billion. CEO Eduardo Menezes pointed to a 10% increase in adjusted EPS and a 12% improvement in adjusted operating income from the base business. The company affirmed full-year guidance implying 7% to 9% earnings growth at the midpoint and raised the quarterly dividend to $1.81, its 44th consecutive annual increase.
The strategic developments centered on hydrogen and capital discipline. Air Products won NASA contracts totaling more than $140 million to supply liquid hydrogen to several facilities and is negotiating an agreement to distribute renewable ammonia for European green-hydrogen production, which it expects to finalize in the first half of 2026. The most consequential number for the bear-bull debate was capital: fiscal 2026 capex was held at about $4 billion, more than $1 billion below the prior year, the first hard evidence of the spending discipline the new leadership team has signaled.
The forward watch items follow directly. The pace of converting the clean-hydrogen pipeline into contracted offtake is the swing factor for whether the premium is earned, with the European ammonia distribution agreement the next concrete milestone. Beyond that, the capex trajectory and any further reduction in megaproject commitments will show whether management continues to prioritize balance-sheet repair, and the affirmed full-year guidance sets the bar each subsequent quarter has to clear.
Peer Cohorts (Per Segment, With Filing Citations)
Core business (reported)
- LIN (LINDE PLC)
- (no filing in the citation store)
- DD (DUPONT DE NEMOURS, INC.)
- (no filing in the citation store)
- WLK (Westlake Corporation)
- (no filing in the citation store)
- LYB (LYONDELLBASELL INDUSTRIES N.V.)
- (no filing in the citation store)
- EMN (EASTMAN CHEMICAL CO)
- (no filing in the citation store)
- ALB (Albemarle Corporation)
- (no filing in the citation store)
- TROX (TRONOX HOLDINGS PLC)
- (no filing in the citation store)
- CBT (Cabot Corporation)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.
Sources
Air Products fiscal Q1 2026 results, January 2026 · Air Products fiscal Q1 2026 earnings call, January 2026